Please ensure Javascript is enabled for purposes of website accessibility
Accessibility Menu
Cogstate Stock Quote

Cogstate (ASX: CGS)

A$1.37
(3.4%)
A$0.04
Price as of April 26, 2024, 2:00 a.m. ET

Cogstate Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
CGS -11.33% +522.73% +44.11% +181%
S&P +23.33% +73.48% +11.63% +341%

Cogstate Company Info

Cogstate Ltd. is a global cognitive science company. It delivers software services to optimize the measurement of cognition in clinical trials, academic research, healthcare and brain injury. The company operates through the following segments: Clinical Trials, Healthcare and Academic Research. The Clinical Trials segment provides solutions to optimize clinical outcome assessments to better measure drug efficacy and safety. The Healthcare segment provides tools to detect patient cognitive impairment and change throughout the continuum of care. The Academic Research provides Technology for researchers studying cognition, from academics to public-private partnerships. Cogstate was founded by David Gordon Darby and Paul Maruff on December 17, 1999 and is headquartered in Melbourne, Australia.

News & Analysis

Valuation

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.